Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
about
Agility in adversity: Vaccines on DemandImmune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentRadiotherapy combination opportunities leveraging immunity for the next oncology practiceThe European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeuticsDNA damage, tumor mutational load and their impact on immune responses against cancerTowards tumor immunodiagnosticsNeoantigen-based cancer immunotherapyTargeted therapies and immunotherapy in non-small-cell lung cancerThe efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysisMechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerAptamers: A Feasible Technology in Cancer ImmunotherapyTackling ALK in non-small cell lung cancer: the role of novel inhibitorsRecent advances in molecular genetics of melanoma progression: implications for diagnosis and treatmentNew targeted treatments for non-small-cell lung cancer - role of nivolumabPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.The role of pembrolizumab in the treatment of advanced non-small cell lung cancerInhibiting Immune Checkpoints for the Treatment of Bladder CancerCheckpoint Inhibitors and Their Application in Breast CancerCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyProfile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancerThe immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsThe steady progress of targeted therapies, promising advances for lung cancerTumor-intrinsic oncogene pathways mediating immune avoidancePrime time for immune-checkpoint targeted therapy at ASCO 2015Gene aberrations for precision medicine against lung adenocarcinomaImmunotherapy for lung cancerCancer immunotherapy: the beginning of the end of cancer?Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterizationThe clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancerCellular and molecular biology of small cell lung cancer: an overviewAdvances in immunotherapy for melanomaPD-1/PD-L1 blockade in cancer treatment: perspectives and issuesMutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor VaccinationProgrammed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleIntegrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicityNovel technologies and emerging biomarkers for personalized cancer immunotherapyPredictors of clinical response to immunotherapy with or without radiotherapyImportance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodiesNew strategies in immunotherapy for non-small cell lung cancer
P2860
Q26252583-513D0169-AD2E-4459-90F3-B5E19B3F13A7Q26738359-47E3C2F3-B8AC-4851-8902-CAE37C7CCDD9Q26738443-D7C04AAF-35AD-412C-B026-6AD05C84EDCBQ26738677-AB83BEF0-A98C-407B-A11D-6A9006628F49Q26738685-56035C47-90E4-40F1-A2F5-23A28B6AD943Q26738691-18DC8E10-DF34-4E56-BA20-F07BD132B53AQ26738693-321BBE62-5DBA-4D48-80BD-EBADB241E0EFQ26738986-69461DFC-1CD9-4BCD-93AE-7C20C1F492E2Q26740280-E9BF8158-A4A5-4E91-BEF9-059596F7CABCQ26740288-917BBAE9-1627-45E9-85EB-0326EF693922Q26740303-F5431FAE-65FB-4893-8EF6-772ECB13B9B2Q26740329-9846C8EB-1ADD-48BD-9345-4E4D334491A8Q26740631-B941853F-4A42-4A89-BC90-93E805BF03B3Q26740988-42B4DA79-CE37-4C28-8827-D41CD206658AQ26741101-EE047FF1-B9D9-414E-9EA3-DC95BCB889F8Q26741529-713F1DFA-E654-454E-963E-D12460707AAFQ26744076-F50FC545-0686-4E5D-BEA2-EBC1172006A8Q26744758-26700A10-785B-412B-A6B2-3F9F225ABF78Q26745442-6ACCBD0C-5DD1-472A-90AE-36276258F0C7Q26745516-822E0F9D-2525-4665-A064-9C915D7AF8D1Q26745590-26D6BC94-BDE5-49C3-83C6-20707C6F9F61Q26745842-02CC94E0-2C19-4E0F-AC8A-B13B671A6611Q26746895-39C3FA41-1DBA-4A0D-B984-CC0CA169F255Q26747707-0E761516-F49B-43D6-8C54-77A4237ED237Q26747711-6E86849C-EF49-4ED5-851C-4ADBE4E5CF04Q26749348-9AEDDCE1-6AD1-4D91-9D89-468B5B05C64FQ26751254-45002E5A-26D0-4DE7-8120-A5B2593028A5Q26752277-97A66CAA-C7A2-432D-80C5-440ECE0FEA8CQ26765060-FFB4FC20-E542-4BF9-9DED-590F00E94203Q26766285-7216947A-8C0A-45EF-86C6-3CA58FDC2E82Q26767029-B880FA67-D6F4-4307-A1ED-3C7E33FBDEADQ26768558-9F50211B-F995-45B8-A739-7CC56B76583FQ26768641-9CB45F53-DF22-40AC-8EAB-B8F22ABFB7C8Q26769044-D2269F25-45B9-42D2-9B94-EB3AC90A032FQ26769734-BB58A461-27BA-4788-8244-58E864A65AEEQ26769744-C361088C-14C2-48EF-8F4D-8878C34775D4Q26770780-FD5CE6FB-4C64-4A8E-B435-DF2BC403C770Q26771870-ABC99B64-6BF2-4051-A9F7-0CFCF5D7C7A2Q26775034-B8C3D5BF-AF5C-4CA5-948F-192A93B90FB5Q26775385-9578A9C9-6BAB-4978-86DB-80BA2C719022
P2860
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Cancer immunology. Mutational ...... in non-small cell lung cancer
@ast
Cancer immunology. Mutational ...... in non-small cell lung cancer
@en
type
label
Cancer immunology. Mutational ...... in non-small cell lung cancer
@ast
Cancer immunology. Mutational ...... in non-small cell lung cancer
@en
prefLabel
Cancer immunology. Mutational ...... in non-small cell lung cancer
@ast
Cancer immunology. Mutational ...... in non-small cell lung cancer
@en
P2093
P2860
P50
P3181
P356
P1433
P1476
Cancer immunology. Mutational ...... in non-small cell lung cancer
@en
P2093
Alexandra Snyder
Andre L Moreira
Billel Gasmi
Cameron Bruggeman
Chris Sander
Edward B Garon
Fawzia Ibrahim
Jedd D Wolchok
Jianda Yuan
Matthew D Hellmann
P2860
P304
P3181
P356
10.1126/SCIENCE.AAA1348
P407
P5008
P577
2015-04-03T00:00:00Z